Related Experiment Video
Updated: May 4, 2026
Ole Isacson: Development of New Therapies for Parkinson's Disease
Published on: April 29, 2007
Parkinson's disease gene therapy: success by design meets failure by efficacy
Raymond T Bartus1, Marc S Weinberg2, R Jude Samulski3
1Ceregene, Inc., San Diego, California, USA; RTBioconsultants, Inc., San Diego, California, USA.
Abstract:
Over the past decade, nine gene therapy clinical trials for Parkinson's disease (PD) have been initiated and completed. Starting with considerable optimism at the initiation of each trial, none of the programs has yet borne sufficiently robust clinical efficacy or found a clear path toward regulatory approval. Despite the immediately disappointing nature of the efficacy outcomes in these trials, the clinical data garnered from the individual studies nonetheless represent tangible and significant progress for the gene therapy field. Collectively, the clinical trials demonstrate that we have overcome the major safety hurdles previously suppressing central nervous system (CNS) gene therapy, for none produced any evidence of untoward risk or harm after administration of various vector-delivery systems. More importantly, these studies also demonstrated controlled, highly persistent generation of biologically active proteins targeted to structures deep in the human brain. Therefore, a renewed, focused emphasis must be placed on advancing clinical efficacy by improving clinical trial design, patient selection and outcome measures, developing more predictive animal models to support clinical testing, carefully performing retrospective analyses, and most importantly moving forward-beyond our past limits.
Insights
Nine gene therapy trials for Parkinson's disease (PD) show safety but lack efficacy. Future research should focus on improving trial design and patient selection for better results in neurodegenerative disease treatment.
Area of Science:
- Neuroscience
- Genetics
- Clinical Medicine
Background:
- Over the past decade, nine gene therapy clinical trials for Parkinson's disease (PD) have been initiated and completed.
- Despite initial optimism, none of these trials have demonstrated sufficient clinical efficacy or a clear path to regulatory approval.
Purpose of the Study:
- To evaluate the safety and efficacy of gene therapy in Parkinson's disease (PD) clinical trials.
- To assess the progress and identify future directions for gene therapy in treating neurodegenerative disorders.
Main Methods:
- Review of data from nine completed gene therapy clinical trials for Parkinson's disease.
- Analysis of safety profiles, vector-delivery systems, and protein generation in the central nervous system (CNS).
Main Results:
- Gene therapy trials for PD have overcome major safety hurdles in the central nervous system (CNS), with no significant adverse events reported.
- These studies demonstrated controlled and persistent generation of biologically active proteins in deep brain structures.
Conclusions:
- While current gene therapy trials for Parkinson's disease have not yet achieved robust clinical efficacy, they represent significant progress in CNS gene therapy safety.
- Future efforts must prioritize enhancing clinical efficacy through improved trial design, patient selection, outcome measures, and predictive animal models.
More Related Videos
08:33Development of an Alpha-synuclein Based Rat Model for Parkinson's Disease via Stereotactic Injection of a Recombinant Adeno-associated Viral Vector
Published on: February 28, 2016
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
Related Concept Videos
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
00:59Gene Therapy
00:59Gene Therapy
01:15Parkinson's Disease: Overview
01:24Parkinson Disease ll: Pathophysiology
01:24Parkinson Disease l: Introduction